O-glycoside Patents (Class 514/25)
  • Patent number: 11357746
    Abstract: The present invention relates to use of a composition comprising D-glyceric acid (DGA), DL-glyceric acid, L-glyceric acid, or hydroxypyruvatic acid and/or their salts or esters. Further, the invention relates to the use of said composition for enhancing direct and indirect mitochondrial metabolism, e.g. the ATP producing electron transport system (ETS), citric acid cycle or tricarboxylic acid cycle, (TCA), and beta oxidation, and also enhancing the shuttling of reducing equivalents from mitochondrial matrix into the cytosol and protein synthesis in the endoplasmic reticulum. Directly related to the above the use of DGA relates also to reducing the formation of reactive oxygen species (ROS). Alleviating, preventing and even healing effects towards extremely wide range of non-communicable diseases materializes.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: June 14, 2022
    Assignee: REPLICON HEALTH OY
    Inventors: Petteri Hirvonen, Peter Eriksson, Risto Kaksonen
  • Patent number: 11337428
    Abstract: An aqueous extract of Larrea tridentata useful in the control of phytopathogens that attack commercial crops, functionalized to increase the ratio of quinones of nordihydroguaiaretic acid.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: May 24, 2022
    Inventors: Juan Genaro Osuna Sanchez, Yolanda Sanchez Salazar, Yolanda Osuna Sanchez
  • Patent number: 11332548
    Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: May 17, 2022
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 11311601
    Abstract: The present invention relates to novel fragments of AIMP1 protein and a composition for improving alopecia and promoting hair growth comprising the same, more specifically it relates to a polypeptide consisting of 4 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28th to 31st amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1, or a polypeptide consisting of an amino acid sequence having 70% or more sequence homology with the polypeptide; a polynucleotide encoding the polypeptide; a pharmaceutical, cosmetic and food composition for improving alopecia and promoting hair growth comprising the polypeptide.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: April 26, 2022
    Assignee: CUREBIO THERAPEUTICS
    Inventors: Sunghoon Kim, Min Chul Park, Younha Kim
  • Patent number: 11306339
    Abstract: A method for the production of a rhamnolipid. The method includes culturing in a fermentation medium an organism capable of producing a rhamnolipid to form a fermentation broth comprising at least one rhamnolipid and having a pH>5; extracting at least one lipophilic impurity from said fermentation broth; acidulating said fermentation broth to form an aqueous medium of pH<5 comprising the at least one rhamnolipid; extracting the at least one rhamnolipid from said acidulated fermentation broth; and separating the at least one rhamnolipid to obtain a purified rhamnolipid.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: April 19, 2022
    Assignee: SUPERBREWED FOOD, INC.
    Inventors: Aharon M. Eyal, Bryan P. Tracy, Christopher Joseph McWilliams
  • Patent number: 11306115
    Abstract: Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: April 19, 2022
    Assignee: ELOXX PHARMACEUTICALS LTD.
    Inventor: Timor Baasov
  • Patent number: 11278483
    Abstract: A cosmetic ingredient comprising crenatoside and acteoside when applied to the skin is useful to provide cosmetic and perfumery benefits.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 22, 2022
    Assignee: GIVAUDAN SA
    Inventors: Fabrice Lefevre, Daniel Auriol, Cyrille Jarrin, Patrick Robe, Romain Reynaud
  • Patent number: 11191729
    Abstract: The use of a granular material which is for orally fast disintegrating tablets and comprises starch and tannic acid allows provision of tablets that can be produced by a simple process with general-purpose production equipment, disintegrate fast and absorbs water in the mouth, and have a proper level of shape retainability for practical use. The present invention also provides a method for producing an orally fast disintegrating tablet, the method comprising compression molding of a granular material for orally fast disintegrating tablets comprising starch and tannic acid, or a mixture of the granular material for orally fast disintegrating tablets and other ingredients (an additive, an active ingredient, and/or the like).
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 7, 2021
    Assignee: Teika Pharmaceutical Co., Ltd.
    Inventors: Takao Shimatani, Yutaka Hasegawa, Hiroko Ito, Takahiro Kawagishi, Naohisa Wada, Atsushi Yamada
  • Patent number: 11191814
    Abstract: A food supplement is disclosed that comprises an extracellular matrix composition of hydrolyzed collagen, hyaluronic acid and glucosamine, ascorbic acid and, optionally, a cannabinoid composition. The food supplement can be given to pet animals for the relief of or prophylaxis of degenerative joint diseases, such as arthritis.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: December 7, 2021
    Assignee: PAW POWER, INC.
    Inventor: Anja Skodda
  • Patent number: 11186812
    Abstract: An optofluidic photoreactor including an optical waveguide having an input, characterized by an evanescent optical field confined along an outer surface of the optical waveguide produced by radiation propagating in the optical waveguide, means for inputting light to the input of the optical waveguide, and a photoactive material disposed substantially only within the evanescent field. A method for optically activating a photoactive material in an optofluidic photoreactor to convert carbon dioxide and water into other molecules that may be useful as a fuel or a chemical feedstock.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: November 30, 2021
    Assignee: CORNELL UNIVERSITY
    Inventors: David Erickson, Perry M. Schein
  • Patent number: 11179408
    Abstract: The present invention relates to the use of cyanoglucoside according to formula (I) and formulations thereof in the prevention and/or treatment of diabetes and/or metabolic syndrome; wherein R1, R2 and R3 are independently selected from an optionally substituted mono- or di-saccharide, —O—R4, —O—C(O)—R4 and halogen, such as Cl, F or Br, wherein R4 is selected from H, alkyl, such as methyl, as well as tautomers, geometrical isomers, optically active forms, pharmaceutically acceptable salts and pharmaceutically active derivative thereof.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: November 23, 2021
    Assignees: UNIVERSITÉ DE GENÈVE, UNIVERSIDADE ESTADUAL PAULISTA JÚLIO DE MESQUITA FILHO
    Inventors: Luiz Leonardo Saldanha, Anne Ligia Dokkedal Bosqueiro, Jose Roberto Bosqueiro, Nathalia Aparecida De Paula Camaforte Henriques, Priscilla Maria Ponce Vareda, Wagner Vilegas, Emerson Ferreira Queiroz, Laurence Marcourt, Jean-Luc Wolfender
  • Patent number: 11173177
    Abstract: The present disclosure relates to use of heparin analogues as inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: November 16, 2021
    Assignee: Aarhus Universitet
    Inventors: Camilla Gustafsen, Peder Sondergaard Madsen, Simon Glerup Pedersen
  • Patent number: 11166973
    Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating viral infections, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: November 9, 2021
    Assignee: Emory University
    Inventors: Dennis C. Liotta, George R. Painter, Gregory R. Bluemling, Abel de la Rosa
  • Patent number: 11160782
    Abstract: A nobiletin composition having high water solubility and a method for easily producing the same are provided. A method for producing a solid dispersion comprising nobiletin, comprising the step of mixing nobiletin or a nobiletin-containing product with a water-soluble hesperidin derivative, and then melting the mixture by heating; and the step of solidifying the melted product by cooling. A nobiletin-containing composition produced by the method.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: November 2, 2021
    Assignee: KAO CORPORATION
    Inventors: Masazumi Iwashita, Masahiro Umehara, Shintaro Onishi, Masaki Yamamoto, Keisuke Yamagami, Takaaki Ishigami
  • Patent number: 11161868
    Abstract: The present invention provides N-acetyl derivatives of sialic acids, including N-acetyl derivatives of Neu5Ac and Neu5Gc. Methods for preparing related precursors and a variety of sialosides are also disclosed.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: November 2, 2021
    Assignee: The Regents of the University of California
    Inventors: Xi Chen, An Xiao, Anoopjit Kooner, Abhishek Santra, Ajit Varki, Hai Yu, Lee-Ping Wang, Wanqing Li
  • Patent number: 11141371
    Abstract: New extracts of Nannochloropsis sp. and related species of Nannochloropsis are suggested, obtainable by treating said microalgae with a solvent selected from the group consisting of C1-C1 aliphatic alcohols, ethyl acetate, water or their mixtures, removing the dissolved extracts from the residues and recovering the pure extracts from the solvent. The extracts show excellent properties particularly in modulating the metabolism of human skin and hair follicles.
    Type: Grant
    Filed: August 8, 2015
    Date of Patent: October 12, 2021
    Assignee: Symrise AG
    Inventors: Lorenzo Zanella, Paolo Pertile
  • Patent number: 11141379
    Abstract: The present invention encompasses prodrug compositions, nanoparticles comprising one or more prodrugs, and methods of use thereof.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: October 12, 2021
    Assignee: Washington University
    Inventors: Gregory M. Lanza, Dipanjan Pan
  • Patent number: 11142492
    Abstract: Methods of isolating phenols from phenol-containing media. The methods include combining a phospholipid-containing composition with the phenol-containing medium to generate a combined medium, incubating the combined medium to precipitate phenols in the combined medium and thereby form a phenol precipitate phase and a phenol-depleted phase, and separating the phenol precipitate phase and the phenol-depleted phase. The methods can further include extracting phenols from the separated phenol precipitate phase. The extracting can include mixing the separated phenol precipitate phase with an extraction solvent to solubilize in the extraction solvent at least a portion of the phenols originally present in the phenol precipitate phase.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: October 12, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Bradley Bolling, Yuwei Wu, Danielle Voss, Matthew Dorris
  • Patent number: 11096935
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: August 24, 2021
    Assignee: VIDAC PHARMA LTD
    Inventors: Vered Behar, Oren Menahem Becker, Reut Yosef Hamo, Eyal Dor-On
  • Patent number: 11090349
    Abstract: An extract from leaves of mulberry is disclosed. The extract has an IC50 value sufficient to inhibit ?-glucosidase I. The extract may comprise 5-40% (w/w) total imino sugars and 20-70% (w/w) total amino acids. The extract may reduce the production of melanin for the treatment of such ailments or diseases caused by pigmentation as freckle, chloasma, striae gravidarum, sensile plaque and melanoma. The extract may also control blood glucose level.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: August 17, 2021
    Inventors: Chen Xie, Yingshu Zou
  • Patent number: 11071718
    Abstract: Provided are methods of treating a neurological or psychiatric disorder in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof in combination with an amount of one or more compounds effective to increase the level of nicotinamide adenine dinucleotide (NAD+) in the subject.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: July 27, 2021
    Assignee: BNIW Ventures LLC.
    Inventors: Guriqbal S. Nandra, Irvin M. Wiesman
  • Patent number: 11058698
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 13, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Koji Yasuda, Leonard Buckbinder, Bernard Lanter, Spencer Cory Peck, Cheri Snedeker, Angela She, Jessica Alexander, Anna Liang, Jenny Liu, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr., Amir H. Moarefi
  • Patent number: 11000535
    Abstract: A composition for inhibiting a liver tumor in an organism is disclosed. The composition includes an activator being 1,2,3,4,6-penta-O-galloyl-Beta-D-glucopyranoside (PGG), wherein PGG is extracted from at least one of Paeonia lactiflora Pall. and Galla Chinesis.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 11, 2021
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yi-Ming Chen, Chia-Hung Yen, Chung-Kuang Lu
  • Patent number: 10988731
    Abstract: A method of creating a protein rich conditioned medium. The method includes culturing mesenchymal stem cells in a container utilizing a first growth medium, allowing a time period for proliferation of the mesenchymal stem cells until a desired level of confluence is achieved in the container, discarding a supernatant from the container, adding a second medium to the container, incubating the mesenchymal stem cells, and collecting the conditioned medium. The method produces significantly higher quantities of byproducts secreted by the mesenchymal stem cells. Byproducts are usable for wound healing, disease treatment, cosmetic, or other beneficial effects when applied or otherwise delivered to a patient.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: April 27, 2021
    Assignee: HOPE BIOSCIENCES, LLC
    Inventors: Hyeonggeun Park, Fred Haisam Khoury
  • Patent number: 10966918
    Abstract: Disclosed are methods of treating skin with topical skin compositions comprising at least one plant extract.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: April 6, 2021
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Florence, David Gan, Michelle Hines
  • Patent number: 10959929
    Abstract: The present disclosure relates to cosmetic agents which, in addition to ethanol and fragrances, contain at least one fixing agent mixture for the fragrances and have a high and long-lasting deodorizing action. Furthermore, the present disclosure relates to the use of these agents for the treatment of body odor.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: March 30, 2021
    Assignee: Henkel AG & Co. KGaA
    Inventor: Thomas Doering
  • Patent number: 10953040
    Abstract: The present disclosure describes compositions comprising ?-lactam antibiotics and branched polyethylenimines (BPEI), having efficacy against various Gram-positive bacteria, for example Gram-positive bacteria having resistance against ?-lactam antibiotics, one non-limiting example of which is Methicillin-resistant Staphylococcus aureus (MRSA). The compositions result in the resensitization of such resistant bacterial strains to traditional antibiotic therapies such as ?-lactam antibiotics.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: March 23, 2021
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Charles V. Rice
  • Patent number: 10953027
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 23, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, John Robert Proudfoot, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Afrand Kamali Sarvestani, Leonard Buckbinder, Bernard Lanter, Ferdinand Edward Massari, Koji Yasuda, Spencer Cory Peck, Cheri Snedeker, Diana Le, Jessica Alexander, Anna Liang, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr.
  • Patent number: 10941111
    Abstract: Disclosed herein is a continuous manufacturing process for lomustine that has a short residence time and 63 percent yield. Major advantages of this process are that the total production cost for lomustine is lower, the product is higher quality, and the manufacturing operation is safer for production personnel.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 9, 2021
    Assignee: Purdue Research Foundation
    Inventors: David H Thompson, Robert Graham Cooks, Christina Ramires Ferreira, Zinia Jaman
  • Patent number: 10940159
    Abstract: A combination immediate/delayed release delivery system for compounds which have short half-life's, such as the antidiabetic remogliflozin etabonate, is provided which provides a dosage form that has two distinct phases of release, a formulation that promotes immediate release of the compound upon ingestion and another formulation which delays the release of the compound so that a dosing regimen of remogliflozin etabonate, once daily, may be achieved while providing effective control of plasma glucose and minimizing the nighttime exposure of this compound. The delivery system includes, but is not limited to, a combination of enteric coating of an immediate release formulation such that a delay in release is provided. Methods for forming the so-described immediate/delayed release delivery system and using such delivery system for treating diabetes are also provided.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: March 9, 2021
    Inventors: James Trinca Green, William Owen Wilkison
  • Patent number: 10927148
    Abstract: Peptides that form adhesive bonds, even in aqueous and/or saline environments, are disclosed. When aggregated, the peptides may be used in methods for producing hydrogels and/or adhesive materials. Synthetic peptide analogs are provided that are designed based on protein sequences found in barnacle adhesive, and may optionally be augmented with chemistry from other organisms that secrete proteins that adhere to substrates. The peptides may be used, for example, in biomedical and aqueous applications. Methods of using the aggregated peptides as adhesives are also provided.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: February 23, 2021
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Christopher R. So, Kathryn J. Wahl
  • Patent number: 10898424
    Abstract: The present invention relates to a blend comprising palmitoyl tripeptide-5, an algae extract, panthenol, water and optionally pullulan and/or sodium hyaluronate.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: January 26, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Mathias Gempeler, Dominik Imfeld, Dirk Weber, Dominique Crestia
  • Patent number: 10874749
    Abstract: A composition of matter comprising an adeno-associated virus (AAV) or other human compatible virus, encoding the gene for Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof, and a neuron specific promoter, wherein the composition is suitable for administration to a patient comprising injecting the AAV or other human compatible virus into the brain by intracranial stereotaxic injunction; wherein the AAV's encoding for the Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof enhance and/or normalize levels of GM1 in neurons, providing both therapeutic relief and disease modifying effects in specific areas of the brain relevant to particular neurodegenerative diseases.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: December 29, 2020
    Assignee: Thomas Jefferson University
    Inventors: Jay S. Schneider, David W. Anderson
  • Patent number: 10870021
    Abstract: Ambrisentan and formulations thereof for use in the treatment and prevention of acute renal failure associated with renal vasoconstriction.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: December 22, 2020
    Assignee: NOORIK BIOPHARMACEUTICALS AG
    Inventors: Iker Navarro, Satish Khanna
  • Patent number: 10822367
    Abstract: The present invention relates to a pharmaceutical composition comprising an acanthoside B compound as an effective ingredient for preventing or treating dementia or for improving a cognitive function. In the present invention, a desalted glasswort extract, and acanthoside B, which is isolated from the extract and acts as an effective ingredient inhibitory of acetylcholine esterase, were found to have an excellent neuroprotective activity through the inhibition of neuroinflammation and to improve memory retention and remarkably enhance spatial cognitive ability as measured by passive avoidance test and Y-maze test in a scopolamine-induced amnesic animal model. The acanthoside B or glasswort extract of the present invention can be applied to a pharmaceutical composition for preventing or treating dementia, a pharmaceutical composition for improving a cognitive function, or a health functional food or feed for improving memory retention and cognitive function.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: November 3, 2020
    Assignee: PHYTO CORPORATION INC.
    Inventors: Deuk-Hoi Kim, Mee-Hyang Kweon, Eun-Ah Cho, Joon Soo Kim, Hyun Joo Yoon, Seon Yeong Park
  • Patent number: 10822430
    Abstract: The invention relates to glycosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glycosaminoglycan derivatives and further to their use as active ingredients of medicaments.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: November 3, 2020
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 10787476
    Abstract: An object of the present invention is to provide glycoamino acid as an amino acid precursor with improved properties (particularly water-solubility, stability in water, bitter taste etc.). The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: September 29, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Wataru Kurosawa, Risa Ubagai
  • Patent number: 10752650
    Abstract: The subject invention provides a novel SL that is widely applicable to various fields including food or beverages, cosmetics, pharmaceuticals, and quasi-drugs. A sophorolipid compound represented by Formula (I) below: (in Formula (I), R1 represents H or a methyl group; R3 and R4 each represents H or an acetyl group; one of five R5 is a saturated or unsaturated fatty acid residue that may have an OH group, and the remaining four R5 are H; R2 represents a C9-18 alkylene group, or C9-18 alkenylene group having 1 to 3 double bonds; R6 represents hydroxy, or may form a single bond together with one of five R7 in the compound represented by Formula (II) below) (in Formula (II), R1? represents H or methyl group; R3? and R4? each represents H or an acetyl group; R2? represents a C9-18 alkylene group, or C9-18 alkenylene group having 1 to 3 double bonds).
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: August 25, 2020
    Assignee: Saraya Co., Ltd.
    Inventors: Michiaki Araki, Yoshihiko Hirata
  • Patent number: 10723750
    Abstract: The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of ?-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: July 28, 2020
    Assignees: La Jolla Institute for Allergy and Immunology, Universiteit Gent, VIB VZW
    Inventors: Dirk Zajonc, Serge Van Calenbergh, Dirk Elewaut, Joren Guillaume
  • Patent number: 10696662
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 30, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • Patent number: 10695319
    Abstract: Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 30, 2020
    Assignees: The Johns Hopkins University, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
    Inventors: Jun Liu, Qingli He, Martin G. Pomper, Il Minn, Biao Yu, Qiaoling Wang
  • Patent number: 10683525
    Abstract: The present invention relates to a method for producing 2-O-glyceryl-?-D-glucopyranoside (?GG; FIG. 1) from a glucosyl donor and a glucosyl acceptor comprising the steps: providing a sucrose phosphorylase (EC 2.4.1.7), incubating said sucrose phosphorylase with a mixture comprising a glucosyl donor and glycerol as glucosyl acceptor and isolating and/or purifying 2-O-glyceryl-?-D-glucopyranoside.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: June 16, 2020
    Assignee: TECHNISCHE UNIVERSITÄT GRAZ
    Inventors: Christiane Luley, Thornthan Sawangwan, Bernd Nidetzky, Mario Müller
  • Patent number: 10682346
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 16, 2020
    Assignee: VIDAC PHARMA LTD.
    Inventors: Vered Behar, Oren Menahem Becker, Reut Yosef Hamo, Eyal Dor-On
  • Patent number: 10603300
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such a
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: March 31, 2020
    Inventors: Saskia Kley, Dania Birte Reiche
  • Patent number: 10568352
    Abstract: The disclosure provides nutritional compositions including a blend of amino acids and polyphenols. These nutritional compositions find use, for example, in treating and preventing EMS and laminitis in equines, as well as generally promoting animal health.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 25, 2020
    Assignee: Wiser Concepts, LLC
    Inventor: Delia Nash
  • Patent number: 10568897
    Abstract: A composition for use in prevention, inhibition and/or treatment of coccidiosis in an animal is disclosed. The composition comprises an effective amount of Bidens pilosa, an active constituent thereof, or an active compound isolated therefrom. In another aspect, a composition for use in enhancing growth in an animal is disclosed. The composition comprising an animal feed and an effective amount of Bidens pilosa, or an isolated active constituent comprising a polyacetylenic compound.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: February 25, 2020
    Assignee: ACADEMIA SINICA
    Inventors: Wen-Chin Yang, Lee-Tian Chang
  • Patent number: 10561678
    Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 18, 2020
    Assignee: Indus Biotech Private Limited
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman
  • Patent number: 10555960
    Abstract: Methods of using and pharmaceutical compositions comprising (2R,3S,4R,5R,6S)-5-amino-6-(((1R,2S,3S,4R,6S)-4,6-diamino-3-(((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2- yl)oxy)-2-hydroxycyclohexyl)oxy)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol are disclosed, including methods of treating or preventing a nonsense mutation mediated disease associated with premature translation termination or a premature stop codon resulting from a germline or somatic nonsense mutation.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: February 11, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventor: Ramil Y. Baiazitov
  • Patent number: 10538794
    Abstract: This disclosure relates to libraries of oligosaccharides comprising multiple individual oligosaccharides derived from cells that contain a tag or detectable marker. In certain embodiments, the tag or detectable marker is an oxygen linked to the oligosaccharides through the first carbon of a sugar ring. In certain embodiments, the disclosure relates to methods of generating the libraries of oligosaccharides using saccharides, e.g., monosaccharides, or a disaccharide, in which hydroxyl groups are chemically acetylated.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: January 21, 2020
    Assignee: Emory University
    Inventors: Tongzhong Ju, Richard Cummings, Matthew Kudelka
  • Patent number: 10525162
    Abstract: The present invention provides a biocompatible hydrogel composition comprising glycolipids and silk fibroin (SF) wherein glycolipid is preferably sophorolipids (SL). The said composition is useful in preparation of 3D scaffold for use in tissue engineering, and in the biomedical field. The present invention also provides a process for preparing such a composition and a process for acceleration of gelation time of silk fibroin (SF) in the presence of sophorolipid.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: January 7, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Parul Dubey, Philem Pushparani Devi, Anuya Amol Nisal, Asmita Ashutosh Prabhune